Primary |
Hodgkin's Disease |
61.7% |
Hodgkin's Lymphoma |
9.7% |
Hodgkin's Disease Refractory |
5.7% |
Product Used For Unknown Indication |
3.7% |
Hodgkin's Disease Recurrent |
3.0% |
Diffuse Large B-cell Lymphoma |
2.7% |
Lymphoma |
2.3% |
Acute Graft Versus Host Disease |
2.0% |
Anaplastic Large-cell Lymphoma |
1.3% |
Non-hodgkin's Lymphoma |
1.3% |
T-cell Lymphoma |
1.3% |
Angioimmunoblastic T-cell Lymphoma |
1.0% |
Mycosis Fungoides |
1.0% |
Drug Use For Unknown Indication |
0.7% |
Hodgkin's Disease Stage Iv |
0.7% |
Hodgkin's Lymphoma |
0.3% |
Acute Myeloid Leukaemia |
0.3% |
Anaplastic Large Cell Lymphoma T- And Null-cell Types |
0.3% |
Germ Cell Cancer |
0.3% |
Lymphomatoid Papulosis |
0.3% |
|
Vomiting |
14.1% |
Febrile Neutropenia |
9.4% |
Pyrexia |
9.4% |
Sepsis |
9.4% |
White Blood Cell Count Decreased |
8.2% |
Pancreatitis |
7.1% |
Pneumonia |
5.9% |
Death |
3.5% |
Stem Cell Transplant |
3.5% |
Thrombocytopenia |
3.5% |
Urticaria |
3.5% |
Weight Decreased |
3.5% |
Gastrointestinal Infection |
2.4% |
Neutropenia |
2.4% |
Oral Candidiasis |
2.4% |
Pancytopenia |
2.4% |
Platelet Count Decreased |
2.4% |
Rash |
2.4% |
Rash Maculo-papular |
2.4% |
Sinus Tachycardia |
2.4% |
|
Secondary |
Hodgkin's Disease |
43.1% |
Anaplastic Large-cell Lymphoma |
13.9% |
Product Used For Unknown Indication |
11.1% |
Anaplastic Large Cell Lymphoma T- And Null-cell Types |
8.3% |
T-cell Prolymphocytic Leukaemia |
8.3% |
Prophylaxis Against Graft Versus Host Disease |
4.2% |
Chemotherapy |
2.8% |
Lymphoma |
2.8% |
Vasculitis Necrotising |
2.8% |
Mycosis Fungoides Refractory |
1.4% |
T-cell Lymphoma Recurrent |
1.4% |
|
Diabetes Mellitus |
7.7% |
Infusion Related Reaction |
7.7% |
Oedema |
7.7% |
Pneumonia |
7.7% |
Pulmonary Toxicity |
7.7% |
Pyrexia |
7.7% |
Respiratory Failure |
7.7% |
Therapeutic Product Ineffective |
7.7% |
Thrombocytopenia |
7.7% |
Transplant Rejection |
7.7% |
Vasculitis Necrotising |
7.7% |
Vomiting |
7.7% |
Weight Decreased |
7.7% |
|
Concomitant |
Anaplastic Large Cell Lymphoma T- And Null-cell Types |
51.2% |
Mycosis Fungoides |
46.5% |
Chronic Lymphocytic Leukaemia Refractory |
2.3% |
|
Sepsis |
66.7% |
Vomiting |
33.3% |
|
Interacting |
Product Used For Unknown Indication |
51.1% |
Hiv Infection |
12.8% |
Antiemetic Supportive Care |
6.4% |
Hodgkin's Disease |
6.4% |
Prophylaxis |
6.4% |
Blood Glucose Increased |
4.3% |
Enzyme Inhibition |
4.3% |
Haematological Malignancy |
4.3% |
Antibiotic Prophylaxis |
2.1% |
Gastrointestinal Disorder |
2.1% |
|
Vomiting |
50.0% |
Drug Interaction |
25.0% |
Sepsis |
25.0% |
|